NO801018L - Diagnostisk fremgangsmaate. - Google Patents
Diagnostisk fremgangsmaate.Info
- Publication number
- NO801018L NO801018L NO801018A NO801018A NO801018L NO 801018 L NO801018 L NO 801018L NO 801018 A NO801018 A NO 801018A NO 801018 A NO801018 A NO 801018A NO 801018 L NO801018 L NO 801018L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- concentration
- dna
- protein
- bleomycin
- Prior art date
Links
- 238000002405 diagnostic procedure Methods 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 201000011510 cancer Diseases 0.000 claims description 48
- 108091006086 inhibitor proteins Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 35
- 210000002966 serum Anatomy 0.000 claims description 31
- 108010006654 Bleomycin Proteins 0.000 claims description 24
- 229960001561 bleomycin Drugs 0.000 claims description 24
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 24
- 230000015556 catabolic process Effects 0.000 claims description 14
- 238000006731 degradation reaction Methods 0.000 claims description 14
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 11
- 229960005542 ethidium bromide Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 3
- 239000013578 denaturing buffer Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 5
- 239000013068 control sample Substances 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 229920005654 Sephadex Polymers 0.000 description 12
- 239000012507 Sephadex™ Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
- 108010017384 Blood Proteins Proteins 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910021538 borax Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000012465 retentate Substances 0.000 description 6
- 235000010339 sodium tetraborate Nutrition 0.000 description 6
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910001868 water Inorganic materials 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 101710096438 DNA-binding protein Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007694 polyacrylamide gel isoelectric focusing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Sink And Installation For Waste Water (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2873279A | 1979-04-10 | 1979-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO801018L true NO801018L (no) | 1980-10-13 |
Family
ID=21845111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO801018A NO801018L (no) | 1979-04-10 | 1980-04-09 | Diagnostisk fremgangsmaate. |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JPS55143441A (fi) |
| KR (1) | KR830002502A (fi) |
| AR (1) | AR222700A1 (fi) |
| AT (1) | AT365343B (fi) |
| AU (1) | AU536522B2 (fi) |
| BE (1) | BE882669A (fi) |
| CH (1) | CH644453A5 (fi) |
| DE (1) | DE3013837A1 (fi) |
| DK (1) | DK149980A (fi) |
| ES (1) | ES8103380A1 (fi) |
| FI (1) | FI801078A (fi) |
| FR (1) | FR2454099A1 (fi) |
| GB (1) | GB2047712B (fi) |
| GR (1) | GR67692B (fi) |
| HU (1) | HU183122B (fi) |
| IE (1) | IE49981B1 (fi) |
| IL (1) | IL59772A (fi) |
| IT (1) | IT1143135B (fi) |
| LU (1) | LU82345A1 (fi) |
| NL (1) | NL8002094A (fi) |
| NO (1) | NO801018L (fi) |
| PH (1) | PH15637A (fi) |
| SE (1) | SE8002602L (fi) |
| ZA (1) | ZA802141B (fi) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3524644A1 (de) * | 1985-07-10 | 1987-01-15 | Heyl Chem Pharm | Undulin und dessen peptidfragmente, verfahren zu deren herstellung und ihre verwendung |
-
1980
- 1980-03-28 PH PH23825A patent/PH15637A/en unknown
- 1980-04-03 SE SE8002602A patent/SE8002602L/ not_active Application Discontinuation
- 1980-04-03 IE IE693/80A patent/IE49981B1/en unknown
- 1980-04-03 FI FI801078A patent/FI801078A/fi not_active Application Discontinuation
- 1980-04-03 AU AU57193/80A patent/AU536522B2/en not_active Ceased
- 1980-04-04 FR FR8007691A patent/FR2454099A1/fr active Granted
- 1980-04-04 IL IL59772A patent/IL59772A/xx unknown
- 1980-04-04 BE BE0/200139A patent/BE882669A/fr not_active IP Right Cessation
- 1980-04-07 JP JP4475080A patent/JPS55143441A/ja active Pending
- 1980-04-08 LU LU82345A patent/LU82345A1/fr unknown
- 1980-04-08 DK DK149980A patent/DK149980A/da not_active IP Right Cessation
- 1980-04-09 ES ES490396A patent/ES8103380A1/es not_active Expired
- 1980-04-09 NO NO801018A patent/NO801018L/no unknown
- 1980-04-09 NL NL8002094A patent/NL8002094A/nl not_active Application Discontinuation
- 1980-04-09 IT IT48370/80A patent/IT1143135B/it active
- 1980-04-10 AR AR280624A patent/AR222700A1/es active
- 1980-04-10 KR KR1019800001518A patent/KR830002502A/ko unknown
- 1980-04-10 AT AT0195780A patent/AT365343B/de not_active IP Right Cessation
- 1980-04-10 ZA ZA00802141A patent/ZA802141B/xx unknown
- 1980-04-10 DE DE19803013837 patent/DE3013837A1/de not_active Withdrawn
- 1980-04-10 CH CH277880A patent/CH644453A5/fr not_active IP Right Cessation
- 1980-04-10 GR GR61652A patent/GR67692B/el unknown
- 1980-04-10 GB GB8011902A patent/GB2047712B/en not_active Expired
- 1980-04-10 HU HU80871A patent/HU183122B/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2454099A1 (fr) | 1980-11-07 |
| IE49981B1 (en) | 1986-01-22 |
| FI801078A (fi) | 1980-10-11 |
| IT8048370A0 (it) | 1980-04-09 |
| NL8002094A (nl) | 1980-10-14 |
| ES490396A0 (es) | 1981-02-16 |
| ZA802141B (en) | 1981-04-29 |
| IE800693L (en) | 1980-10-10 |
| JPS55143441A (en) | 1980-11-08 |
| HU183122B (en) | 1984-04-28 |
| IT1143135B (it) | 1986-10-22 |
| SE8002602L (sv) | 1980-12-09 |
| BE882669A (fr) | 1980-10-06 |
| AR222700A1 (es) | 1981-06-15 |
| AU5719380A (en) | 1980-10-16 |
| AU536522B2 (en) | 1984-05-10 |
| FR2454099B1 (fi) | 1984-01-27 |
| PH15637A (en) | 1983-03-11 |
| ATA195780A (de) | 1981-05-15 |
| ES8103380A1 (es) | 1981-02-16 |
| LU82345A1 (fr) | 1980-12-16 |
| CH644453A5 (fr) | 1984-07-31 |
| GB2047712A (en) | 1980-12-03 |
| DK149980A (da) | 1980-10-11 |
| AT365343B (de) | 1982-01-11 |
| DE3013837A1 (de) | 1980-10-30 |
| GR67692B (fi) | 1981-09-07 |
| KR830002502A (ko) | 1983-05-30 |
| IL59772A0 (en) | 1980-06-30 |
| IL59772A (en) | 1983-05-15 |
| GB2047712B (en) | 1983-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Varnum et al. | Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer | |
| Metzgar et al. | Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. | |
| US7763435B2 (en) | Method for diagnosis of alzheimer's disease with determination of LASP-1 immunoreactivity | |
| US4270924A (en) | Diagnostic method for detecting cancer | |
| EP0012768B1 (en) | Quantitative testing for vitamin b12 | |
| Hansen et al. | Electrophoretic analysis of the glycan microheterogeneity of orosomucoid in cancer and inflammation | |
| DE60107022T2 (de) | Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum | |
| US6759204B2 (en) | Method and kit for early diagnosis of cancer | |
| Dermer et al. | Enhancement techniques for detecting trace and fluid-specific components in two-dimensional electrophoresis patterns. | |
| Moncure et al. | Immunological and histochemical evaluation of marrow aspirates in patients with prostatic carcinoma | |
| NO801018L (no) | Diagnostisk fremgangsmaate. | |
| Kuriyama et al. | Clinical evaluation of γ‐seminoprotein in prostate cancer | |
| US4424278A (en) | Cancer detection procedure using an acyl carrier protein | |
| EP0206065A2 (en) | Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids | |
| US5955287A (en) | Method of determining level of biological substances elevated in the presence of cancer and other neoplasms | |
| Buffone et al. | Characterization and evaluation of immunochemical methods for the measurement of fecal α 1-antitrypsin | |
| Abe et al. | Rheumatoid factor-like substance and antistreptolysin O antibody in leprosy serum | |
| US4493898A (en) | Method for detecting and monitoring cancer | |
| FI60567B (fi) | Preparat foer anvaendning vid diagnostisering av kancer och foerfarande foer dess framstaellning | |
| Knapp | Partial Characterisation of an Oncofetal Pancreatic Antigen: Its Role in the Differential Diagnosis and Therapy of Patients with Pancreatic Cancer | |
| Mirowski et al. | Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer | |
| US5804368A (en) | Method for screening for prostate cancer by measuring apolipoprotein D levels in body fluid | |
| RU2147124C1 (ru) | Способ оценки состояния гомеостаза | |
| Mustala et al. | A New Modification for the Determination of 5-Ydroxy-Indole-Acetic Acid (5HIAA) in Urine Unspecific Nitrosonaphthol Reactions and Their Elimination | |
| SU1490650A1 (ru) | Способ количественного определени стероидных гормонов |